- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
A Relatively Safe Breast Cancer Combination Therapy Proves Effective
The study published in the New England Journal of Medicine found nearly 100% survival with adjuvant paclitaxel and trastuzumab.
Patients with small, node-negative, HER2-positive breast cancers had a 3-year survival approaching 100% with adjuvant paclitaxel and trastuzumab (Herceptin), a multicenter, prospective trial showed.
The 406 patients included in the study had 3-year invasive disease-free survival (IDFS) of 98.7%. After excluding contralateral HER2-negative recurrences and nonbreast cancers, investigators identified seven disease-specific recurrences.
Safety results were generally good, as relatively few patients had grade 3 peripheral neuropathy, heart failure, or asymptomatic declines in left ventricular ejection fraction (LVEF), as reported online in the New England Journal of Medicine.
Link to the complete article on Medpage Today: http://bit.ly/1BPBva4
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
